Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C. Mueller ER, et al. Among authors: van maanen r. Neurourol Urodyn. 2019 Feb;38(2):779-792. doi: 10.1002/nau.23919. Epub 2019 Jan 15. Neurourol Urodyn. 2019. PMID: 30644570 Free PMC article. Clinical Trial.
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.
Weber MA, Chapple CR, Gratzke C, Herschorn S, Robinson D, Frankel JM, Ridder AM, Stoelzel M, Paireddy A, van Maanen R, White WB. Weber MA, et al. Among authors: van maanen r. Blood Press Monit. 2018 Jun;23(3):153-163. doi: 10.1097/MBP.0000000000000320. Blood Press Monit. 2018. PMID: 29578880 Free PMC article. Clinical Trial.
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Abrams P, et al. Among authors: van maanen r. Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19. Eur Urol. 2015. PMID: 24612659 Clinical Trial.
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D. Herschorn S, et al. Among authors: van maanen r. BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8. BJU Int. 2017. PMID: 28418102 Free article. Clinical Trial.
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Robinson D, Kelleher C, Staskin D, Mueller ER, Falconer C, Wang J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Hakimi Z, Herschorn S. Robinson D, et al. Among authors: van maanen r. Neurourol Urodyn. 2018 Jan;37(1):394-406. doi: 10.1002/nau.23315. Epub 2017 Jul 13. Neurourol Urodyn. 2018. PMID: 28704584 Clinical Trial.
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Gratzke C, et al. Among authors: van maanen r. Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. Eur Urol. 2018. PMID: 29866467 Free article. Clinical Trial.
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, Newgreen D, Ridder A, Paireddy A, van Maanen R. Abrams P, et al. Among authors: van maanen r. World J Urol. 2017 May;35(5):827-838. doi: 10.1007/s00345-016-1908-1. Epub 2016 Aug 11. World J Urol. 2017. PMID: 27514371 Clinical Trial.
40 results